Search results
Results from the WOW.Com Content Network
Polystyrene sulfonate is usually supplied in either the sodium or calcium form. It is used as a potassium binder in acute and chronic kidney disease for people with hyperkalemia (an abnormally high blood serum potassium level). [3]
Potassium binders are medications that bind potassium ions in the gastrointestinal tract, thereby preventing its intestinal absorption. This category formerly consisted solely of polystyrene sulfonate, a polyanionic resin attached to a cation, administered either orally or by retention enema to patients who are at risk of developing hyperkalaemia (abnormal high serum potassium levels).
Hyperkalemia is an elevated level of potassium (K +) in the blood. [6] [1] Normal potassium levels are between 3.5 and 5.0 mmol/L (3.5 and 5.0 mEq/L) with levels above 5.5 mmol/L defined as hyperkalemia. [3] [4] Typically hyperkalemia does not cause symptoms. [1] Occasionally when severe it can cause palpitations, muscle pain, muscle weakness ...
Importantly, the use of the potassium-enriched salt substitute did not significantly increase the risk of high potassium levels (hyperkalemia). How salt substitutes work to lower stroke risk
Hyperkalemia, particularly if severe, is a marker for an increased risk of death. [14] However, there is disagreement regarding whether a modestly elevated levels directly causes problems. One viewpoint is that mild to moderate hyperkalemia is a secondary effect that denotes underlying medical problems. [ 14 ]
Overdoses cause hyperkalemia, which can lead to paresthesia, cardiac conduction blocks, fibrillation, arrhythmias, and sclerosis. [ 13 ] Because of the risk of small-bowel lesions, the US Food and Drug Administration (FDA) requires some potassium salts containing more than 99 mg (about 1.3 mEq) to be labeled with a warning, [ 14 ] while ...
A typical TTKG in a normal person on a normal diet is 8-9. During hyperkalemia or high potassium intake, more potassium should be excreted in the urine and the TTKG should be above 10. Low levels (<7) during hyperkalemia may indicate mineralocorticoid deficiency, especially if accompanied by hyponatremia and high urine Na.
In clinical trials supported by Novo Nordisk, gallstones were reported in 1.5 percent of participants taking a 0.5 mg dose of semaglutide and 0.4 percent of those taking the 1 mg dose. No cases of ...